Microbiome Connect : Human - EU 2020 | Kisaco Research
Please click here for KR Covid-19 Update

Designing microbiome-modulating therapeutics for the treatment of neurological, cancer, metabolic and gastro-intestinal indications.

Designing Microbiome-Modulating Therapeutics and Diagnostics for the Treatment of Neurological, Cancer, Metabolic and Gastro-Intestinal Indications.

Register
London, UK
11-12 November, 2020

“This event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science. Kisaco has gone out of their way to include speakers and perspectives not found elsewhere. I look forward to attending again.”

KC Microbiome Communications Group

Why Attend

The gut microbiome is becoming an increasingly important druggable target for pharma companies through a range of modalities from FMT to small molecule and even phage. 2020 looks set to be a pivotal year for the microbiome industry with a handful of companies (including Seres, Rebiotix and Finch Therapeutics) set to release ground-breaking phase 3 clinical data. We’re a step away from market approval, but there’s still so much to learn…

Major advances in shotgun metagenomic sequencing and computational biology allow us to see what’s going on at a strain-specific and metabolomic level of detail. Elucidating the key metabolites and mechanisms of action in both extra-intestinal and intestinal indications is a key objective in 2020/2021 and is a cornerstone of the discussion at Microbiome Connect: Human. 

Join key opinion leaders and 50+ expert speakers across three dedicated tracks of content to examine the latest preclinical and clinical data in extra-intestinal and intestinal indications. This is your opportunity to find out how others plan on translating gut-microbiome research into therapeutics that have the power to treat Oncological, Neurological, Gastro-Intestinal & Metabolic diseases.

Previously known as European Microbiome Congress, Microbiome Connect: Human EU is all about connecting leading academics and biotech companies presenting preclinical and clinical data, to network, educate and share knowledge. 

200+
Attendees
50:50
Ratio of Academics - Industry
5+
Microbiome Niches Covered
50+
Leading Top Speakers
10+
Hours of Dedicated Networking

What's new for 2020

  1. Deep dive into the microbiome’s mechanistic and metabolomic role in Neurological, Oncological, Gastro-Intestinal & Metabolic indications with three distinct scientific streams of the latest pre-clinical and clinical data.

  2. Assess how leading biotech companies and academics are designing a range of therapeutic microbiome-modulating modalities from small-molecule and Phage to rationally designed live bio-therapeutics and FMT. 

  3. Meet your next commercial partner and learn exactly what Pharma and VCs are looking for in terms of pre-clinical and clinical data to finance academic spin-outs and later-stage clinical trials.

Speakers

 

Adrien Nivoliez

CEO
Biose

Adrien Nivoliez

CEO
Biose

Adrien Nivoliez

CEO
Biose
 

Aletta Kraneveld

Professor of Pharmacology
Utrecht University

In 2016 Aletta Kraneveld (MSc Pharmacy & pharmacologist) was appointed as full professor Interdisciplinary Translational Pharmacology at the Faculty of Science and the Faculty of Veterinary Medicine of the Utrecht University. She has published >120 papers (H-index: 42). Besides science, she is/has been an active member of several boards of (inter)national scientific and societal organizations (Dutch Society of Pharmacology, EPHAR, IUPHAR, Netherlands Federation of Innovative Drug research; Diversity committee UU; Food Lives-NL).

Aletta Kraneveld

Professor of Pharmacology
Utrecht University

Aletta Kraneveld

Professor of Pharmacology
Utrecht University

In 2016 Aletta Kraneveld (MSc Pharmacy & pharmacologist) was appointed as full professor Interdisciplinary Translational Pharmacology at the Faculty of Science and the Faculty of Veterinary Medicine of the Utrecht University. She has published >120 papers (H-index: 42). Besides science, she is/has been an active member of several boards of (inter)national scientific and societal organizations (Dutch Society of Pharmacology, EPHAR, IUPHAR, Netherlands Federation of Innovative Drug research; Diversity committee UU; Food Lives-NL).

Kraneveld’s current research interests involve targeting the interaction between innate and adaptive immunity as well as host-microbiome interactions in chronic (inflammatory) diseases with pharmaceutical as well as nutritional interventions. The Kraneveld group is focusing research to in depth study the role of the gut-immune-brain-axis in neurodevelopmental and neurodegenerative disorders. Results will further enhance the knowledge of the interaction of microbiome with the immune and nervous systems in chronic conditions in the gut and CNS. Aletta Kraneveld has set up a program that is a (inter)national neuro-immune platform where academia, patient organisations and industry meet for research on the gut-immune-brain axis as target for medicine and medical food concepts. 

 

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Dr Andrew Morgan, DuPont Fellow and Chief Scientist, DuPont Nutrition & Health Over 35 years’ experience in research and development including  human health & nutrition, animal nutrition, industrial enzymes and crop science as well as innovation management, business development and corporate venturing including founding member of DuPont Nutrition & Health’s Microbiome Venture

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Dr Andrew Morgan, DuPont Fellow and Chief Scientist, DuPont Nutrition & Health Over 35 years’ experience in research and development including  human health & nutrition, animal nutrition, industrial enzymes and crop science as well as innovation management, business development and corporate venturing including founding member of DuPont Nutrition & Health’s Microbiome Venture

 

Anna Ettore

Senior Immunologist Team Leader
4D Pharma

Anna Ettore

Senior Immunologist Team Leader
4D Pharma

Anna Ettore

Senior Immunologist Team Leader
4D Pharma
 

Dr. Sabine Hazan-Steinberg

CEO
ProgenaBiome

Dr. Sabine Hazan-Steinberg, acclaimed Gastroenterologist and founder of ProgenaBiome, LLC, Ventura Clinical Trials, LLC, and Malibu Specialty Center, is at the forefront of medicine. She recently turned her focus from doing Fecal Microbiota Transplant, also known as FMT to better understand the microbiome. FMT is the process of recolonizing the gut with good flora in hopes to cure specific disease. Spearheading advancement in medicine, this treatment is being explored by Dr. Hazan following the leadership of Dr. Thomas Borody and the late Dr.

Dr. Sabine Hazan-Steinberg

CEO
ProgenaBiome

Dr. Sabine Hazan-Steinberg

CEO
ProgenaBiome

Dr. Sabine Hazan-Steinberg, acclaimed Gastroenterologist and founder of ProgenaBiome, LLC, Ventura Clinical Trials, LLC, and Malibu Specialty Center, is at the forefront of medicine. She recently turned her focus from doing Fecal Microbiota Transplant, also known as FMT to better understand the microbiome. FMT is the process of recolonizing the gut with good flora in hopes to cure specific disease. Spearheading advancement in medicine, this treatment is being explored by Dr. Hazan following the leadership of Dr. Thomas Borody and the late Dr. Sydney Finegold to treat Crohn’s disease, Celiac disease, Alzheimer’s disease, Alopecia areata, Autism, Obesity, Metastatic cancer, and recurrent infection with Clostridium difficile.  She is a firm believer in the potential to recolonize your gut back to health recognizing that much work is still left to be done.

Well-prepared for these endeavors, Dr. Hazan was the first woman accepted in to the University of Florida as a Clinical Gastroenterology Fellow, and has continued to be a pioneer in medicine. She has over 22 years of experience in clinical trials and has also been published in numerous medical journals. In the past year, she has served as the series editor for the journal Practical Gastroenterology, for a series on the microbiome. As a trailblazer from the start, she believes in using logic when practicing medicine and tries to think outside the box. “I always remind myself that much like every fingerprint is different, every patient’s symptom is different, and one cannot practice like a robot.”

 

Isabelle De Cremoux

CEO
Seventure Partners

Isabelle De Cremoux

CEO
Seventure Partners

Isabelle De Cremoux

CEO
Seventure Partners
 

Benno Haarman

Head of Program, Mood and Anxiety Disorders
University of Groningen

Benno Haarman

Head of Program, Mood and Anxiety Disorders
University of Groningen

Benno Haarman

Head of Program, Mood and Anxiety Disorders
University of Groningen
 

Benoit Levast

Preclinical Scientist
Maat Pharma

Benoit Levast

Preclinical Scientist
Maat Pharma

Benoit Levast

Preclinical Scientist
Maat Pharma
 

Christopher Reyes

Co-Founder & CEO
Bloom Science

Christopher Reyes

Co-Founder & CEO
Bloom Science

Christopher Reyes

Co-Founder & CEO
Bloom Science
 

Georg Zeller

Team Leader, Structural & Computational Biology
European Molecular Biology Laboratory

Georg Zeller

Team Leader, Structural & Computational Biology
European Molecular Biology Laboratory

Georg Zeller

Team Leader, Structural & Computational Biology
European Molecular Biology Laboratory
 

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America.

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America. Grégory also has experience managing IP, business development and general management.  He is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he has driven the development of several pharmaceutical products from the laboratory through to market authorisation. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations, so far has raised over 10M€ in a mixture of grant and VC funding and begins human clinical trials this year.

 

Imke Mulder

Research Director
4D Pharma

Imke Mulder

Research Director
4D Pharma

Imke Mulder

Research Director
4D Pharma
 

Ben Mullish

Cinical Research Fellow, Dept. of Metabolism, Digestion and Reproduction
Imperial College London

Ben Mullish

Cinical Research Fellow, Dept. of Metabolism, Digestion and Reproduction
Imperial College London

Ben Mullish

Cinical Research Fellow, Dept. of Metabolism, Digestion and Reproduction
Imperial College London
 

Dr James Kinross

Senior Lecturer in Colorectal Surgery
Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery.

Dr James Kinross

Senior Lecturer in Colorectal Surgery
Imperial College London

Dr James Kinross

Senior Lecturer in Colorectal Surgery
Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery. He was awarded a Royal College of Surgeons of England training fellowship during his PhD and he was funded by the Academy of Medical Sciences as an early stage lecturer. He is a visiting Professor at the Royal College of Surgeons of Ireland. He is currently funded by Bowel and Cancer research and the Imperial BRC.

 

James McIlroy

Founder
EnteroBiotix

James McIlroy

Founder
EnteroBiotix

James McIlroy

Founder
EnteroBiotix
 

Jos Seegers

Operational Manager
Caelus

Jos Seegers

Operational Manager
Caelus

Jos Seegers

Operational Manager
Caelus
 

Karine Clement

Professor of Nutrition
INSERM/Sorbonne University

Karine Clement

Professor of Nutrition
INSERM/Sorbonne University

Karine Clement

Professor of Nutrition
INSERM/Sorbonne University
 

Laura Steenbergen

Assistant Professor
University of Leiden

Laura Steenbergen

Assistant Professor
University of Leiden

Laura Steenbergen

Assistant Professor
University of Leiden
 

Morten Isaksen

CEO
Bio-Me

Morten Isaksen

CEO
Bio-Me

Morten Isaksen

CEO
Bio-Me
 

Nader Yaghoubi

Co-founder & CEO
Symbiotix Biotherapies

Nader Yaghoubi

Co-founder & CEO
Symbiotix Biotherapies

Nader Yaghoubi

Co-founder & CEO
Symbiotix Biotherapies
 

Patrice Garnier

CEO
Amabiotics

Patrice Garnier

CEO
Amabiotics

Patrice Garnier

CEO
Amabiotics
 

Paul Wilmes

Assistant professeur
Luxembourg Centre for Systems Biomedicine, University of Luxembourg

Paul Wilmes

Assistant professeur
Luxembourg Centre for Systems Biomedicine, University of Luxembourg

Paul Wilmes

Assistant professeur
Luxembourg Centre for Systems Biomedicine, University of Luxembourg
 

Robert Jan Brummer

Professor
Orebro University

Robert Jan Brummer

Professor
Orebro University

Robert Jan Brummer

Professor
Orebro University
 

Arne Materna Ph.D

Vice President Products
Cosmos ID

Arne Materna Ph.D

Vice President Products
Cosmos ID

Arne Materna Ph.D

Vice President Products
Cosmos ID
 

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Shahram Lavasani

Founder & CEO
ImmuneBiotech
 

Yolanda Sanz Herranz

Senior Researcher
IARA-CSIC

Yolanda Sanz Herranz

Senior Researcher
IARA-CSIC

Yolanda Sanz Herranz

Senior Researcher
IARA-CSIC
 

Dr. Henrik Bjørn Nielsen

Chief Scientific Officer
Clinical Microbiomics

Dr. Henrik Bjørn Nielsen

Chief Scientific Officer
Clinical Microbiomics

Dr. Henrik Bjørn Nielsen

Chief Scientific Officer
Clinical Microbiomics
 

Ravi Starlz

CEO
BioPlx

Ravi Starlz

CEO
BioPlx

Ravi Starlz

CEO
BioPlx
 

Dr. Machteld Tiemessen

Team Leader, Immunology
Danone Nutricia Research

In July 2018, Dr. Machteld Tiemessen joined Danone Nutricia Research as Team Leader Immunology in the Global Center of Excellence Immunology. Since obtaining her PhD in Immunology in 2004, which was focused on the induction of oral tolerance in food allergy, she has held many different positions, both at academia and in industry. The main topic at the start of her career was the investigation of the role and mechanisms of regulatory T cells in normal immune responses and during diseases, such as allergy and cutaneous T cell lymphoma.

Dr. Machteld Tiemessen

Team Leader, Immunology
Danone Nutricia Research

Dr. Machteld Tiemessen

Team Leader, Immunology
Danone Nutricia Research

In July 2018, Dr. Machteld Tiemessen joined Danone Nutricia Research as Team Leader Immunology in the Global Center of Excellence Immunology. Since obtaining her PhD in Immunology in 2004, which was focused on the induction of oral tolerance in food allergy, she has held many different positions, both at academia and in industry. The main topic at the start of her career was the investigation of the role and mechanisms of regulatory T cells in normal immune responses and during diseases, such as allergy and cutaneous T cell lymphoma. In 2010, she received a Veni-grant to further elucidate the role of Wnt-signaling in peripheral T cell function (not restricted to regulatory T cells). After 14 years of research at several universities in The Netherlands and King’s College in London, the United Kingdom, she started in 2013 at Johnson & Johnson to apply her immunological knowledge in the field of viral vaccines. At J&J, she led various discovery projects, with a focus on early discovery projects in the field of oncology vaccines and in the field of polio vaccines.

Who Will Be There

50%
Academics
20%
Biotech
20%
Pharma & Food Companies
10%
Investors

Academics

Biotech

Pharma & Food Companies

Investors

Submit your poster

Looking to showcase your recent work to the microbiome community?

Our dedicated poster area is the perfect way to get your research noticed and further involve yourself in the congress. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).

At the Congress, your presentation will be displayed in a dedicated poster area which can be viewed during the networking break.

CLICK HERE TO MAKE A SUBMISSION

Associate Partner

Senior Event Partner

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Agenda

Fill in your details to download our full agenda which showcases the speakers as well as key topics we will be covering in Microbiome Connect: Human USA.

What you can expect from the 2020 Congress:

  • 200+ Academic and Industry Leaders Onsite
  • 50+ Thought Leaders on the Speaker Faculty
  • 3 Distinct Streams

Download our Agenda

Venue

London, UK

The congress will take place in London, the venue is to be confirmed.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.